Nasopharyngeal carcinoma: an evolving paradigm
The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …
Management of locally recurrent nasopharyngeal carcinoma
As a consequence of the current excellent loco-regional control rates attained using the
generally accepted treatment paradigms involving intensity-modulated radiotherapy for …
generally accepted treatment paradigms involving intensity-modulated radiotherapy for …
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
W Fang, Y Yang, Y Ma, S Hong, L Lin, X He… - The Lancet …, 2018 - thelancet.com
Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …
plus cisplatin, are generally considered the first-line standard of care for patients with …
Deep learning for automated contouring of primary tumor volumes by MRI for nasopharyngeal carcinoma
Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor
proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from …
proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from …
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
L Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia… - The Lancet, 2016 - thelancet.com
Background Outcomes are poor for patients with recurrent or metastatic nasopharyngeal
carcinoma and no well established first-line chemotherapy is available for the disease. We …
carcinoma and no well established first-line chemotherapy is available for the disease. We …
Nasopharyngeal carcinoma
YP Chen, ATC Chan, QT Le, P Blanchard, Y Sun, J Ma - The Lancet, 2019 - thelancet.com
Nasopharyngeal carcinoma is characterised by distinct geographical distribution and is
particularly prevalent in east and southeast Asia. Epidemiological trends in the past decade …
particularly prevalent in east and southeast Asia. Epidemiological trends in the past decade …
TRIM21 inhibits irradiation-induced mitochondrial DNA release and impairs antitumour immunity in nasopharyngeal carcinoma tumour models
Although radiotherapy can promote antitumour immunity, the mechanisms underlying this
phenomenon remain unclear. Here, we demonstrate that the expression of the E3 ubiquitin …
phenomenon remain unclear. Here, we demonstrate that the expression of the E3 ubiquitin …
Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized …
Purpose The contribution of adjuvant chemotherapy after chemoradiation therapy (CRT) in
nasopharyngeal cancer (NPC) remains controversial. Plasma Epstein-Barr virus (EBV) DNA …
nasopharyngeal cancer (NPC) remains controversial. Plasma Epstein-Barr virus (EBV) DNA …
Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1
X Hong, N Liu, Y Liang, Q He, X Yang, Y Lei, P Zhang… - Molecular cancer, 2020 - Springer
Abstract Background Circular RNAs (circRNAs), a new type of noncoding RNA (ncRNA),
have been identified as significant gene expression regulators and are involved in cancer …
have been identified as significant gene expression regulators and are involved in cancer …
The role of Epstein–Barr virus in nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is a metastasis-prone malignancy closely associated
with the Epstein–Barr virus (EBV). Despite ubiquitous infection of EBV worldwide, NPC …
with the Epstein–Barr virus (EBV). Despite ubiquitous infection of EBV worldwide, NPC …